OncologyAstraZeneca
AstraZeneca Reports Phase 3 FLAURA2 Results for Tagrisso Plus Chemotherapy in EGFR NSCLC
BMI
Biotechnology Media Insights
Editorial Team · November 18, 2023
AstraZeneca announces Phase 3 FLAURA2 trial results showing Tagrisso plus chemotherapy significantly improves progression-free survival in EGFR-mutated NSCLC.
AstraZeneca today announced results from the Phase 3 FLAURA2 trial evaluating Tagrisso (osimertinib) plus platinum-based chemotherapy versus Tagrisso alone as first-line treatment for EGFR-mutated non-small cell lung cancer. The trial met its primary endpoint, demonstrating a significant improvement in progression-free survival with the combination.
BMI
Biotechnology Media Insights
Published by Biotechnology Media Insights — your trusted source for pharmaceutical, biotech, and life sciences news.